Evidence map›Paper›PMID 32843084›Full record

ArticleTrials2020

Efficacy and safety of fire needle therapy for blood stasis syndrome of plaque psoriasis: protocol for a randomized, single-blind, multicenter clinical trial.

Liu Liu, Yi Lu, Xiao-Ning Yan, Su-Qing Yang, Li-Ping Gong, Ling-E Li, Yi-Ding Zhao, Qing-Feng Yin, Rui-Ping Wang, Yue-Peng An and 5 more

Registry-linked trialOpen access · goldAbstract readClinical Trial Protocol
In one paragraph

Article in Trials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03953885 (Fire Needle Therapy on Plaque Psoriasis With Blood Stasis Syndrome), which is not on this map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03953885 naunknown statusnot on this map

Fire Needle Therapy on Plaque Psoriasis With Blood Stasis Syndrome: A Randomized, Single-blind, Multicentre Clinical Trial

TypeinterventionalSponsorShanghai Yueyang Integrated Medicine HospitalRan2019 to 2021Enrolled92ConditionsPlaque PsoriasisArmsFire needle, Fire needle Placebo
3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 1 country.

Liu LiuDepartment of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China.
Yi LuDepartment of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China.
Xiao-Ning YanDepartment of Dermatology, Shaanxi Hospital of Traditional Chinese Medicine, Xi'an, 710003, Shannxi, China.
Su-Qing YangDepartment of Dermatology, First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, 150040, Heilongjiang, China.
Li-Ping GongDepartment of Dermatology, The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, 330006, Jiangxi, China.
Ling-E LiDepartment of Dermatology, Traditional Chinese Medicine Hospital of Shijiazhuang, Shijiahzuang, 050011, Hebei, China.
Yi-Ding ZhaoDepartment of Dermatology, Shaanxi Hospital of Traditional Chinese Medicine, Xi'an, 710003, Shannxi, China.
Qing-Feng YinJiangsu Famous Medical Technology Co. Ltd, Nanjing University of Traditional Chinese Medicine, Floor 2, Building 19, Nanjing, 210029, China.
Rui-Ping WangOffice of Clinical Medical Research Center, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China.
Yue-Peng AnDepartment of Dermatology, First Affiliated Hospital of Heilongjiang University of Traditional Chinese Medicine, Harbin, 150040, Heilongjiang, China.
Gang HuangDepartment of Dermatology, The Affiliated Hospital of Jiangxi University of Traditional Chinese Medicine, Nanchang, 330006, Jiangxi, China.
Jin-Fang ZhangDepartment of Dermatology, Traditional Chinese Medicine Hospital of Shijiazhuang, Shijiahzuang, 050011, Hebei, China.
Xiao-Ying SunDepartment of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China.
Xin LiDepartment of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China. 13661956326@163.com.ORCID http://orcid.org/0000-0003-2525-9679
Bin LiDepartment of Dermatology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, 200437, China. 18930568129@163.com.
Shanghai University of Traditional Chinese Medicine · CNAffiliated Hospital of Jiangxi University of Traditional Chinese Medicine · CNFirst Affiliated Hospital of Heilongjiang University of Chinese Medicine · CNShaanxi Provincial Hospital of Traditional Chinese Medicine · CNNanjing University · CN

Funding

the National Key Research and Development Program of China 2018YFC1705303
6 · The paper itself

Abstract

backgroundFire needle therapy is a characteristic treatment in traditional Chinese medicine (TCM). An increasing number of studies have indicated that fire needle treatment for psoriasis provides satisfactory results with few side effects and a low recurrence rate. We herein describe the protocol for a multicenter, randomized, single-blind, placebo-controlled trial that will provide high-quality evidence on the efficacy and safety of fire needle therapy for plaque psoriasis.

methodsNinety-two patients with blood stasis syndrome (BSS) of plaque psoriasis will be enrolled and randomly assigned to receive fire needle therapy (intervention group) or fire needle control therapy (control group) once a week for 4 weeks. The Psoriasis Area and Severity Index (PASI) score will serve as the major efficacy index, while the body surface area (BSA), Physician Global Assessment (PGA) score, Dermatology Life Quality Index (DLQI) score, patient-reported quality of life (PRQoL), visual analog scale (VAS) score for itching, TCM symptom score, and relapse rate will be assessed as secondary outcomes. The PASI score, BSA, PGA score, and VAS score for itching will be evaluated at baseline and during the 4-week treatment and follow-up periods. DLQI score, PRQoL, and TCM symptom score will be assessed at baseline and during the treatment period. Recurrence will be evaluated during the follow-up period. Safety assessments include vital sign monitoring, routine blood tests, blood biochemistry, routine urine tests, pregnancy tests, physical examinations, and adverse-event recording. SAS software will be used for data analysis. The data network platform will be designed by the data management center of Nanjing Ningqi Medical Technology Co., Ltd. DISCUSSION: It is believed that fire needle therapy can activate the meridians, promote blood circulation, and regulate skin immunity. BSS of plaque psoriasis is related to not only immune dysfunction but also poor or stagnant blood flow. We anticipate that the results of the trial described in this protocol will provide strong evidence for the safety and efficacy of fire needle therapy for BSS of plaque psoriasis.

trial registrationClinicaltrials.gov NCT03953885 . Registered on May 15, 2019. Name: Fire Needle Therapy on Plaque Psoriasis with Blood Stasis Syndrome.

Indexed as

NeedlesPsoriasisAcupuncture TherapyDouble-Blind MethodHumansMedicine, Chinese TraditionalMicrocirculationMulticenter Studies as TopicQuality of LifeRandomized Controlled Trials as TopicSeverity of Illness IndexSingle-Blind MethodTreatment OutcomeBlood stasis syndromeFire needle therapyPlaque psoriasisRandomized controlled trialStudy protocol

Identifiers

PMID32843084
PMCPMC7446129
OpenAlexW3080705009

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.